Clinical Trial

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial (SCHOLAR-2)

The purpose of this study is to evaluate whether is it safe and effective to continue trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in patients with early stage HER-2 positive breast cancer who develop mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction. There will be up to 20 participants enrolled at Augusta University with a total of 130 at all sites.

• Lymphatic System
• Breast Cancer
• Heart Failure
• Oncology